



Diabetic retinopathy (DR), a major complication of diabetes
mellitus, is one of the leading causes of blindness worldwide. Early
diagnosis and prevention of retinopathy in diabetic individuals is
crucial for preventing vision loss. Prolonged hyperglycemia causes
irreversible pathological changes in the retina, leading to
proliferative DR with retinal neovascularization and diabetic
macular edema (DME) in some individuals (Mohamed et al., 2007;
Cheung et al., 2010).
Treatment of DR can only be achieved through an enhanced
understanding of disease pathogenesis; however, because most
structural, functional and biochemical studies cannot be carried
out in human subjects, animal models are essential for studying
DR pathology, and thus for developing new and better treatments.
Clinical features of DR
DR is widely regarded as a microvascular complication of diabetes.
Clinically, DR can be classified into non-proliferative DR (NPDR)
and proliferative DR (PDR) (Cheung et al., 2010). NPDR is
characterized ophthalmoscopically by the presence of
microaneurysms and dot and blot hemorrhages (Fig. 1A). NPDR
has been further subdivided into progressive stages: mild, moderate
and severe. Severe NPDR (also called preproliferative DR) shows
increased retinal microvascular damage as evidenced by cotton
wool spots, venous beading, venous loops and intra-retinal
microvascular abnormalities (IRMAs). Capillary non-perfusion and
degeneration of the retina can be detected in individuals with
diabetes following intravascular injection of fluorescein. If left
untreated, PDR (characterized by abnormal retinal
neovascularization) can develop (Fig. 1B). A clinically important
outcome of PDR is retinal and vitreous hemorrhage and tractional
retinal detachment (Cheung et al., 2010).
DME can occur at any stage (i.e. along with NPDR or PDR) and
is now the most common cause of vision loss due to DR (Cheung
et al., 2010).
Epidemiology and risk factors
Diabetes affects more than 300 million people worldwide, and is
expected to affect an estimated 500 million by 2030 (International
Diabetes Federation, 2011). Studies have shown that nearly all
individuals with type 1 diabetes [also known as insulin-dependent
diabetes mellitus (IDDM)] and more than 60% of individuals with
type 2 diabetes (non-insulin-dependent diabetes mellitus) have
some degree of retinopathy after 20 years. Current population-
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Diabetic retinopathy (DR) is the most common microvascular complication of diabetes and one of the major causes of
blindness worldwide. The pathogenesis of DR has been investigated using several animal models of diabetes. These
models have been generated by pharmacological induction, feeding a galactose diet, and spontaneously by selective
inbreeding or genetic modification. Among the available animal models, rodents have been studied most extensively
owing to their short generation time and the inherited hyperglycemia and/or obesity that affect certain strains. In
particular, mice have proven useful for studying DR and evaluating novel therapies because of their amenability to
genetic manipulation. Mouse models suitable for replicating the early, non-proliferative stages of the retinopathy have
been characterized, but no animal model has yet been found to demonstrate all of the vascular and neural
complications that are associated with the advanced, proliferative stages of DR that occur in humans. In this review, we
summarize commonly used animal models of DR, and briefly outline the in vivo imaging techniques used for
characterization of DR in these models. Through highlighting the ocular pathological findings, clinical implications,
advantages and disadvantages of these models, we provide essential information for planning experimental studies of
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based studies suggest that about one-third of the diabetic
population have signs of DR and approximately one tenth have
vision-threatening stages of retinopathy, including PDR and DME
(Wong et al., 2006; Wong et al., 2008; Wang et al., 2009; Zhang et
al., 2010).
People with diabetes are 25 times more likely to become blind
than non-diabetics. In fact, reports have shown that 50% of
diabetics will become blind within 5 years following diagnosis of
PDR, if left untreated (Ciulla, 2004; Klein, 2008; Wong et al., 2009).
The number of people with DR is rapidly increasing owing to a
dramatic rise in the prevalence of type 2 diabetes, reflecting the
increased prevalence of obesity and metabolic syndrome observed
in recent years (Cheung et al., 2010; Raman et al., 2010).
The three major risk factors for DR are prolonged (1) diabetes,
(2) hyperglycemia and (3) hypertension, which have been shown
to be consistently associated with DR in epidemiological studies
and clinical trials (Wong et al., 2006; Wong et al., 2008; Wang et
al., 2009; Cheung et al., 2010; Grosso et al., 2011). Dyslipidemia
and body mass index might also be risk factors for DR, but
associations have not been as consistent (Lim and Wong, 2011;
Benarous et al., 2011; Dirani et al., 2011; Sasongko et al., 2011).
Emerging evidence supports a genetic component for DR, but
specific genes associated with the disease have not been clearly
identified despite large studies (Liew et al., 2006; Abhary et al., 2009;
Sobrin et al., 2011). It remains difficult to predict which diabetic
individuals will progress from NPDR to PDR.
Pathophysiology of DR
The pathogenesis of the development of DR is highly complex
owing to the involvement of multiple interlinked mechanisms
leading to cellular damage and adaptive changes in the retina (Frank,
2004). Hence, the fundamental cause(s) of DR has not been
elucidated completely despite years of clinical and laboratory
investigation. In the past, retinopathy has been characterized
largely by its microvascular abnormalities, including endothelial cell
dysfunction, vessel leakage, and vascular occlusion and
degeneration (Curtis et al., 2009). Recent evidence, however,
indicates that retinal complications of diabetes are a composite of
functional and structural alterations in both the microvascular and
neuroglial compartments (Antonetti et al., 2006; Curtis et al., 2009;
Villarroel et al., 2010; Barber et al., 2011). The exact mechanisms
by which hyperglycemia initiates the vascular or neuronal
alterations in retinopathy have not been completely defined (Curtis
et al., 2009; Villarroel et al., 2010). The cellular damage in the retina
has been speculated to be caused by several mechanisms, including
increased flux through the polyol pathway, production of advanced
glycation end products (AGEs), increased oxidative stress and
activation of the protein kinase C (PKC) pathway, but many of these
hypotheses have yet to be validated in human studies or clinical
trials (Frank, 2004; Cheung et al., 2010).
DR also shares similarities with chronic inflammatory diseases:
it causes increased vascular permeability, edema, inflammatory cell
infiltration, tissue destruction, neovascularization, and the
expression of pro-inflammatory cytokines and chemokines in the
retina. Increased expression of vasoactive factors and cytokines
probably plays an important role in mediating the structural and
functional changes in the retina (Khan and Chakrabarti, 2007;
Wirostko et al., 2008). Recent studies strongly suggest that
inflammation is also important in the pathogenesis of early stages
of experimental DR (Kern, 2007; Liou, 2010; Tang and Kern, 2011),
although studies in humans have not found a consistent association
between systemic markers of inflammation and retinopathy
(Nguyen et al., 2009; Lim et al., 2010). Thus, it remains uncertain
whether inflammation also plays a crucial role in the development
and progression of DR in humans. Some of the major pathways
and factors involved in the pathogenesis of DR are shown in 
Fig. 2.
Outstanding questions regarding DR etiology and
treatment 
The currently available treatments for advanced stages of DR,
including PDR and DME, are laser photocoagulation, surgical
vitrectomy or intraocular injections of steroids and vascular
endothelial growth factor (VEGF) inhibitors. Although these
treatments have had high success rates, they are not useful for early
stages of DR, and do not completely eliminate the risk of blindness
(Cheung et al., 2010). Laser therapy is inherently destructive, with
unavoidable side effects, and is not effective in reversing vision loss.
The new approaches involving anti-VEGF therapy also have
potential ocular and systemic risks (Cheung et al., 2010; Truong et
al., 2011). Thus, new treatment strategies that are preventative
and/or can provide interventions earlier in diabetes to delay or
prevent the progression of early NPDR are needed.
In this regard, it is crucial to more fully establish the underlying
mechanisms and causes for DR. Studies suggest that multifactorial
approaches intervening at the hemodynamic, metabolic and
cytokine levels will delay the development of DR. However, the basic
fundamental mechanism(s) of hyperglycemic influence or
regulation of retinal vessels is not completely understood. Despite
the large number of experimental studies being conducted on the
etiology and treatment of DR in various laboratories, some of the
important issues that remain unanswered are: (1) the mechanisms
that link neural impairment in early diabetes to the development
of retinal vascular abnormalities; (2) the potential role of
inflammation in diabetes-induced retinal neurodegeneration; (3)
the specific retinal layers that are vulnerable to metabolic imbalance
in DR; and (4) the genetic basis of DR.
Further studies using appropriate animal models are required
to provide answers to some of these questions, which will provide
the basis for new treatment approaches that prevent or delay the
onset of DR.
Fig. 1. Clinical features of DR. Fundus photographs of human patients
showing (A) early non-proliferative diabetic retinopathy (NPDR) and (B)















    




Animal models of diabetic retinopathyPERSPECTIVE
Animal models of DR
During the last two decades, extensive research with animal models
of diabetes has been carried out. To date, several species – including
mice, rats, cats, dogs, pigs and non-human primates – have been
used as models to provide valuable information on the cellular and
molecular aspects of pathogenesis of DR. Diabetes in animals is
usually induced with chemicals such as alloxan or streptozotocin
(STZ), by surgical pancreatectomy, or spontaneously by selective
breeding or genetic manipulation. Most experimental studies on
DR to date have used animal models of type 1 diabetes (Cheta,
1998; Kern, 2009; Zheng and Kern, 2010). Recently, many transgenic
and knockout mouse models have also been developed to study
the molecular pathways involved in DR pathology. In the following
sections, we review currently available animal models of DR,
beginning with a description of the various techniques used for in
vivo characterization. We then briefly discuss studies of DR
performed using each model, comment on their contributions to
investigating the pathogenesis of DR, and highlight their advantages
and disadvantages. Retinal lesions of DR observed in small and
higher animal models are summarized in Tables 1 and 2,
respectively.
Characterization of DR in animal models
The use of appropriate imaging techniques to analyze animal
models of human DR is essential to experimentally study and
characterize the disease. Eyes collected at necropsy can be subjected
to sensitive histological techniques (such as trypsin digest) to study
the retinal vasculature in detail. In addition, various molecular and
biochemical techniques (such as quantitative PCR, microarray,
western blotting, as well as protein, enzyme and cytokine assays)
can be carried out to study the expression of various genes and
proteins in the eyes. While the animals are alive, the vascular and
non-vascular alterations of DR (Cunha-Vaz, 2007) can be monitored
in the same animal over time using various techniques, including
electrophysiological testing, fundus photography (FP), fundus
fluorescein angiography (FFA) and optical coherence tomography
(OCT); these techniques are briefly discussed below.
Electrophysiological tests
Electrophysiological tests of retinal function are the most
commonly used non-invasive technique for studying visual function
in animal models. These tests include electroretinography (ERG),
pattern ERG (PERG), multi-focal ERG (mfERG) and visually evoked
potential. Studies using ERG revealed functional abnormalities
before the evidence of vascular changes in the eyes of diabetic rats
(Kohzaki et al., 2008). Alterations in retinal electrical responses,
which arise from the neural retina, are one of the earliest
manifestations of DR. ERG studies on diabetic animals have shown
reduced a- and b-wave amplitude (Li et al., 2002), and prolonged
implicit time in the oscillatory potentials (OPs) (Hancock and Kraft,
2004).
FP and FFA
Retinal vasculature photographs obtained with FP provide a
relatively insensitive tool to monitor the progression of DR, but
are adequate for providing important information about the severity
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Fig. 2. Flow diagram showing the major key factors involved in the pathogenesis of DR and the clinical symptoms evident at different stages of DR. DR
is a multifactorial disease involving several pathological mechanisms, including increased oxidative stress, inflammation, the polyol pathway leading to sorbitol
accumulation, production of advanced glycation end products (AGEs) and activation of the protein kinase C (PKC) pathway. These pathways can in turn activate
the production of cytokines and many vasoactive factors, such as vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF),
which are vital in mediating the structural and functional changes of DR. Clinically significant diabetic macular edema (DME) can occur in the late stages of DR
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Table 1. Retinal lesions reported in small animal models of DR
Animal model Type of diabetes
Age of onset of
diabetes     Retinal lesions References
Rats
STZ Type 1 3 days after STZinjection
• Pericyte loss
• Vascular leakage
• Blood retinal barrier breakdown
• Ganglion cell loss
• Endothelial cell damage
• Vascular occlusion of retinal capillaries
• Thicker capillary BM
Robison et al., 1991; Anderson et al.,
1995; Miyamoto et al., 1999; Xu et al.,






• Thicker capillary BM
Kern and Engerman, 1995
BB Type 1 2-5 months
• Pericyte loss
• Acellular capillaries
• Blood retinal barrier breakdown
• Thicker capillary BM
Blair et al., 1984; Sima et al., 1985
WBN/Kob Type 1 9-21 months
• Acellular capillaries
• Thicker capillary BM
Miyamura et al., 1998; Bhutto et al.,
1999; Tsuji et al., 2009




• Retinal detachment with fibrous
proliferation
Yamada et al., 2005; Kakehashi et al.,
2006; Sasase et al., 2010
ZDF Type 2 1-2 months
• Pericyte loss
• Acellular capillaries
• Thicker capillary BM
Danis et al., 1993; Yang et al., 2000;
Behl et al., 2008
OLETF Type 2 4-5 months
• Microaneurysms
• Tortuosity
• Loop formations of capillaries
• Vessel caliber irregularity
• Thicker capillary BM
Bhutto et al., 2002; Lu et al., 2003
GK Type 2 1-2 months • Increased EC:pericyte ratios Agardh et al., 1997
Mice




• Apoptosis of vascular cells
• Ganglion cell loss
• Thinning of retina






• Thicker capillary BM
Kern and Engerman, 1996a
NOD Type 1 8 months
• Loss of retinal microvessels
• Disordered focal proliferation of new
vessels
Makino et al., 1980; Shaw et al., 2006;
Lee et al., 2008
db/db Type 2 1-2 months
• Pericyte loss
• Acellular capillaries
• Blood-retinal barrier breakdown
• Thicker capillary BM
Midena et al., 1989; Clements et al.,
1998; Cheung et al., 2005
Ins2Akita Type 1 1 month
• Increased vascular permeability
• Acellular capillaries
• Thinning of retina
• Ganglion cell loss
Barber et al., 2005; Gastinger et al.,
2008
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of retinopathy in patients, including vessel caliber changes, swelling
of vessels, abnormal new growth of vessels on retinal surface and
tortuosity. FFA, which monitors the flow of a fluorescent dye
through the retinal vasculature, is useful for demonstrating vascular
abnormalities, non-perfusion and vascular leakage. Neither FP nor
FFA has been extensively used in animal studies, owing to the rapid
development of cataracts in many species, and the fact that small
animals’ eyes are small, highly curved globes, which prevent light
rays from focusing on the retina. Moreover, FFA cannot be used
easily in albino animals or in the non-pigmented portions of retina
in animals having a tapetum (dogs, cats) (Hawes et al., 1999). Fig.
3 shows a comparison of FFA performed in both B6 wild-type
(pigmented) and Balb/c albino (non-pigmented) mice.
OCT
Measurement of retinal thickness has been used as an indicator of
progressive neural retinal pathology in animal models of retinal
degeneration, but the degree of degeneration that occurs in diabetic
animals is considerably less than in retinal degeneration models
and is more difficult to measure reproducibly. High-resolution OCT
measures retinal thickness non-invasively in rodents (as in humans),
and recent machines can produce images with some features of
retinal histology. Studies have also shown that ERG amplitude loss
is highly correlated with retinal thinning as measured by OCT (Li
et al., 2001; Fischer et al., 2009). Similarly, reduced retinal thickness
has been demonstrated in diabetic mice using OCT (Rakoczy et
al., 2010). Retinal thickening has been detected with OCT in
monkeys (Sakurai et al., 2009) and dogs (Panzan et al., 2004), and,
using magnetic resonance imaging, also in diabetic rats (Berkowitz
et al., 2007). Detailed validation of structural and functional lesions
of DR in mice is available in a review by Kern et al. (Kern et al.,
2010a).
Emerging techniques to measure retinal vascular caliber
Human epidemiological studies have shown that measurement of
retinal vascular caliber from photographs might provide clues to
early pathological processes in pre-diabetes, diabetes and DR
(Nguyen et al., 2007; Nguyen et al., 2008; Rogers et al., 2008; Wong,
2011). An insight into the retinal vessel caliber changes in animal
models of DR could thus potentially help to characterize the
structure and pathology of the microcirculation, and to examine
its relationship to systemic vascular diseases in diabetes. Currently,
there are no well-established methods to study the retinal vessel
caliber changes in animal models. Recently, a semi-automated
computer-based quantitative program to measure retinal vascular
caliber from retinal photographs of rodents has become available,
which is identical to the program used in large epidemiological
studies of both diabetic and non-diabetic human populations (Fig.
4A,B). This novel imaging software measures subtle retinal vessel
caliber changes in rodents (Fig. 4C,D), which might be markers of
early microvascular dysfunction in diabetes. Such developments
will open the door for advanced quantitative assessments in animal
models, which could substantially contribute to a better
understanding of the pathogenesis and prediction of DR.
Table 2. Retinal lesions of DR reported in higher animal models of DR 
Animal models Type of diabetes Retinal lesions        References 
Dog Type 1 
• Pericyte loss 
• Microaneurysms 
• Thicker capillary BM 
Gardiner et al., 1994; Kern and Engerman, 1996b 
Galactosemic dogs – 
• Pericyte loss 
• Acellular capillaries 
• Microaneurysms 
• IRMAs 
• Retinal hemorrhages 
Takahashi et al., 1993; Kador et al., 1995; Kern and 
Engerman 1996b; Kobayashi et al., 1998 
Cat Type 1 
• Acellular capillaries 
• Microaneurysms 
• Vascular leakage 
• Tortuosity 
• Thicker capillary BM 
Mansour et al., 1990; Hatchell et al., 1995; 
Linsenmeier et al., 1998; Budzynski et al., 2005 
Pig Type 1 
• Retinal microvasculopathy 
• Thicker capillary BM 





• Cotton wool spots 
• Macular edema 
Tso et al., 1988 
Type 2 
• Acellular capillaries 
• Cotton wool spots 
• Intraretinal hemorrhages 
• Microaneurysms 
• IRMAs 
• Hard exudates in the macula 
• Decreased RGC layer 

















    
   D
M
M
Disease Models & Mechanisms 449
Animal models of diabetic retinopathy PERSPECTIVE
Rodent models of DR
Various rodent models have been used for studying the molecular
mechanisms underlying the pathogenesis of DR. These models are
easy to handle, relatively inexpensive, have short reproductive cycles
and have a similar genetic background to humans, hopefully
allowing experimental results to be extrapolated. Rodent models
of DR vary with respect to species (predominantly rat or mouse),
strain, method of diabetic induction and duration of diabetes.
Advanced techniques of genetic manipulation, such as tissue-
specific transgenic expression and targeted gene knockout, have
increased the relative importance of mouse models for experiments
that specifically require genetically engineered models. Thus, these
animals provide a remarkable platform to investigate the
pathogenesis of at least the early stages of the retinopathy, because
genetic alterations of selected metabolic and pathophysiological
mechanisms are now possible.
However, a major criticism of using rodents to model DR is that
they might not exactly mirror the human condition, especially with
regard to the extent of pathology. Rodent models reproduce most
aspects of the early stages of DR, but have not been found to
reproducibly develop the late, neovascular stage of the disease,
probably owing to the short lifespan of the animals and thus the
shorter duration of diabetes.
Chemically induced diabetic models
Diabetes can be induced in animals using STZ or alloxan, which
destroy pancreatic -cells and thereby induce type 1 diabetes.
Rodents that have been made diabetic in this manner have been
studied for up to 24 months in a hyperglycemic yet healthy
condition, by providing them with small amounts of insulin every
few days. This approach reproduces early symptoms of DR, such
as loss of retinal pericytes and capillaries, thickening of the vascular
basement membrane (BM), vascular occlusion and increased
vascular permeability (Kern and Mohr, 2007; Kern, 2009; Zheng
and Kern, 2010). Physiological and biochemical changes in the
retina begin to appear between 1-2 months after the onset of
hyperglycemia in STZ-induced diabetic rats. Diabetes-induced
non-vascular changes (neuronal and glial) are seen before the
development of changes in vascular cells and might contribute to
the pathology of the vascular disease in this model (Barber et al.,
1998; Zeng et al., 2001; Kohzaki et al., 2008). However, there are
variations in the reported retinal biochemistry and
histopathological response to diabetes between species and also
within the same species. In fact, a recent report studied the
differences in the rate at which early stages of DR develop in three
different rat strains (Sprague Dawley, Lewis and Wistar) with
diabetes induced by STZ. After 8 months of diabetes, Lewis rats
showed the most accelerated loss of retinal capillaries and retinal
ganglion cells (RGCs), whereas Wistar rats showed degeneration
of the capillaries without significant neurodegeneration and
Sprague Dawley rats showed no lesions at this time point (Kern et
al., 2010b).
STZ-induced mouse models were not frequently used for studies
on DR in the past because it was more difficult to induce diabetes
in mice than in rats and was difficult to keep the tiny animals alive
once diabetic. These problems have been overcome more recently.
STZ-induced diabetic B6 mice demonstrated acellular capillaries,
apoptosis of vascular cells and pericyte ghosts in the retina, the
hallmark of early characteristics of DR (Feit-Leichman et al., 2005),
at ~6 months after the onset of diabetes. Advanced proliferative
retinal changes did not develop in these mice within the study
duration (18 months of diabetes). Whether or not mice develop
loss of RGCs is controversial. At 10-14 weeks after STZ treatment,
these mice demonstrated loss of RGCs, and significant thinning of
the inner and outer layers of the retina (Martin et al., 2004; Barber
et al., 2005). Other studies, however, found no evidence of RGC
loss in diabetic mice (Asnaghi et al., 2003; Feit-Leichman et al., 2005;
Gastinger et al., 2006). These diabetic models are mostly used to
demonstrate early changes of DR. Studies of advanced proliferative
retinal changes cannot be carried out in these models because they
die before PDR could be detected.
eNOS–/– mice
Recently, the effects of single genes on the development of DR have
been assessed by inducing diabetes with STZ in transgenic or gene
knockout mice. For example, Li et al. investigated the pathogenic
role of endothelial nitric oxide synthase (eNOS) dysfunction in the
Fig. 3. Fundus fluorescein angiography (FFA) images show the
comparison between normal B6 (pigmented) and Swiss albino (non-
pigmented) mice. Normal (A) B6 (pigmented) and (B) Swiss albino (non-
pigmented) mice. FFA cannot be used in albino mice owing to the absence of
pigment, which produces severe glare.
Fig. 4. Retinal vascular caliber measurement. The measurement of retinal
vessel caliber in human (A,B) and mouse (C,D) with fundus imaging, using
semi-automated computer-based quantitative program (SIVA). The white
arrow indicates the artery, the black arrow indicates the vein and an asterisk (*)
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development of DR by inducing diabetes using STZ in eNOS
knockout (eNOS–/–) mice (Li et al., 2010). The retinal vasculature
of eNOS–/– mice develops normally and is associated with increased
vascular-associated neuronal NOS activity that compensates for
the eNOS deficiency in the retina. STZ-induced diabetes in these
mice showed accelerated retinal complications of DR when
compared with age-matched STZ-induced diabetic B6 wild-type
mice. The retinal complications included increased vessel leakage,
gliosis, acellular retinal capillaries and retinal capillary BM
thickening. Further studies using this model will be useful for
investigating the cellular and molecular mechanisms of DR,
including gliotic responses in retinal Muller cells.
Spontaneously diabetic rat models
Zucker diabetic fatty rats
Zucker diabetic fatty (ZDF) rats are genetic models of type 2 (non-
insulin-dependent) diabetes and become hyperglycemic at 6-7
weeks of age. These rats usually die at ~1 year of age, but can be
maintained without treatment if supplemented with glucose of
more than 500 mg/dl. Studies demonstrated pericyte loss, a thicker
retinal capillary BM, and an increased number of endothelial
intercellular junctions and focal nodules in ZDF rats. This model
is thought to be useful for pharmacological intervention studies
because it is naturally and severely type 2 diabetic, showing
quantifiable retinal vascular changes. In addition, same-sex
littermates can be used as controls (Danis and Yang, 1993; Ottlecz
et al., 1993; Yang et al., 2000).
WBN/Kob rats
The WBN/Kob rat is also a spontaneously type 2 diabetic strain,
in which hyperglycemia occurs at 9 months of age. Thickened
capillary BM and acellular capillaries in the retina have been
reported in this model (Miyamura and Amemiya, 1998; Matsuura
et al., 1999). Proliferative changes were reported in the pre-retinal
vitreous of these rats, showing intra-retinal angiopathy
accompanied by newly formed vessels and significant hyalinization
of intra-retinal vessels (Tsuji et al., 2009). Hence, this might be useful
as an animal model for progressive DR, but the neovascularization
has not been confirmed. Microaneurysms, the early clinical sign
of human NPDR, and arterio-venous shunts, which are associated
with severe stages of human NPDR, were not observed in this model
(Bhutto et al., 1999).
Otsuka Long-Evans Tokushima fatty rats
Otsuka Long-Evans Tokushima fatty (OLETF) rats spontaneously
develop type 2 diabetes with severe obesity. The retinal
ultrastructural changes observed in OLETF rats are similar to
those seen in diabetic individuals (Miyamura et al., 1999; Lu et
al., 2003), but do not include hemorrhages or exudates. There is
significant thinning of the inner nuclear and photoreceptor layers
of the retina, a decrease in the height of the retinal pigment
epithelial (RPE) cells, thickened capillary BM and poorly
developed basal infoldings in these rats. Abnormal ERG was also
reported in sucrose-fed OLETF rats (Hotta et al., 1997). However,
it has been suggested that OLETF rats are not suitable for
studying DR because the formation of acellular capillaries and
pericyte ghosts typical of human DR are not accelerated in these
rats (Matsuura et al., 2005).
Goto-Kakizaki rats
The Goto-Kakizaki (GK) rat is a spontaneous model of non-obese
type 2 diabetes and develops chronic hyperglycemia at 4-6 weeks
of age (Goto et al., 1988). Diabetic GK rats demonstrated an
increased ratio of retinal endothelial cells to pericytes (Agardh et
al., 1997), and reduced retinal blood flow without changes in major
retinal vessel diameters, at an early stage of diabetes (Miyamoto et
al., 1996). Because of the moderate and stable diabetic state, this
rat model is useful for investigating the retinal microcirculatory
changes caused by type 2 diabetes over an extended period of time
(Miyamoto et al., 1996).
Spontaneously diabetic Torii rats
The spontaneously diabetic Torii (SDT) rat is a non-obese type 2
diabetes model that develops hyperglycemia at 20 weeks of age and
can survive for long periods without insulin treatment. SDT rats
exhibit tractional retinal detachment with fibrous proliferation, and
possibly neovascularization, without retinal ischemia. The
development of neovascularization in the absence of ischemia
makes this model considerably different from the
neovascularization that has been observed in diabetic individuals
(Yamada et al., 2005). Thus, the model needs additional study before
it can be considered as a model of DR. Studies showed a reduction
in the amplitude of ERG b-waves and OPs. Because OPs arising
from amacrine cells are a sensitive measure of retinal ischemia,
these studies indicate the development of inner retinal ischemia in
these rats (Sasase, 2010).
Biobreeding rats
The biobreeding (BB) rat is a spontaneous model of type 1 diabetes
that develops diabetes between the age of 40 and 140 days. These
rats exhibit retinal lesions, including pericyte loss, BM thickening,
capillary degeneration and an absence of microaneurysms after 8-
11 months of diabetes (Sima et al., 1985). Pancreas transplantation
has been shown to inhibit the development of retinal microvascular
lesions in this model (Chakrabarti et al., 1987). However, very few
studies of DR have been reported using this model, so its advantages
and disadvantages cannot be judged.
Spontaneously diabetic mouse models
Non-obese diabetic mice
Non-obese diabetic (NOD) mice spontaneously develop type 1
diabetes owing to autoimmune destruction of insulin-producing
pancreatic -cells by CD4+ and CD8+ T cells (Makino et al., 1980).
Studies have shown the loss of retinal microvessels, reduced
perfusion of the retina and disordered focal proliferation of vessels
in NOD mice (Shaw et al., 2006; Lee and Harris, 2008). It is reported
that angiotensin II and thromboxane mediates the venule-
dependent arteriolar vasoconstriction. Only a few reports on DR
have been published using this model.
db/db mice
The db/db (Leprdb) mouse is deficient for the leptin receptor and
spontaneously develops type 2 diabetes associated with obesity at
4-8 weeks of age. Six-month-old db/db mice have been shown to
exhibit early features of DR, such as pericyte and endothelial cell
loss (Midena et al., 1989), BM thickening (Clements et al., 1998)
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15 months, these mice demonstrated distinct DR symptoms,
including blood-retinal barrier (BRB) breakdown, pericyte loss,
neuroretinal apoptosis, glial reactivation, possible
neovascularization and acellular capillaries in the retina (Cheung
et al., 2005). Reports show that db/db mice have some specific
advantages for the study of the retinal microcirculation. These mice
are darkly pigmented and hence the fluorescence of labeled
elements circulating in the choroid can be masked by their pigment
epithelium.
Ins2Akita mice
The Ins2Akita (Akita) mouse contains a dominant point mutation
in the gene encoding insulin-2 that induces spontaneous type 1
diabetes in the B6 mouse strain. Heterozygous male Akita mice
develop hyperglycemia as early as 4 weeks of age. After 12 weeks
of hyperglycemia, the retinas were found to have increased vascular
permeability, degenerate capillaries and alterations in the
morphology of astrocytes and microglia with increasing duration
of diabetes. Furthermore, increased retinal cell apoptosis was
identified, accompanied by a distinct reduction in the thickness of
the inner plexiform layer and inner nuclear layer (Barber et al.,
2005). These mice showed loss of RGCs from the peripheral retina
within the first 3 months of diabetes, as well as marked alterations
to the morphology of surviving cells (Gastinger et al., 2008).
Another study demonstrated a significant reduction in the total
number of cholinergic and dopaminergic amacrine cells in Akita
mice (Gastinger et al., 2006). This model has been studied up to
15-18 months of age, but mortality increased significantly towards
the end of this duration (T. S. K., unpublished data).
This model could be useful for exploring the molecular
mechanisms involved in the initiation and early progression of DR.
In addition, it is an ideal model for evaluating the neuroprotective
effects of drugs because of the quantifiable loss of RGCs in a
relatively short time (4-5 months). Use of this model is increasing
among researchers interested in DR.
Mouse models of proliferative retinopathy
Despite many attempts to establish suitable models that accurately
reflect the features of late human DR, very few animal models
develop severe DR with large areas of retinal non-perfusion and
neovascularization. Hence, researchers have turned to non-diabetic
animals to study proliferative retinopathy. The widely used rodent
models of proliferative retinopathy to study neovascularization are
those in which VEGF is overexpressed in photoreceptors (such as
Kimba mice and mice in which VEGF expression is driven by the
rhodopsin promoter) (Okamoto et al., 1997; Tee et al., 2008), mice
overexpressing insulin-like growth factor-1 (IGF1) in the retina
(Ruberte et al., 2004), oxygen-induced retinopathy (Gole et al., 1990;
Holmes and Duffner, 1996) and branch retinal vein occlusion
(Zhang et al., 2007). These models induce possible
neovascularization and retinal detachment in the absence of
diabetes. For example, transgenic mice with increased expression
of IGF1 in the retina exhibit signs of diabetes-like eye conditions,
including pericyte loss, retinal capillary BM thickening, venule
dilatation, IRMAs and possibly retinal neovascularization (Ruberte
et al., 2004). Kimba mice, generated through photoreceptor-specific
overexpression of human VEGF165 protein, demonstrate retinal
neovascular changes, increased permeability, pericyte and
endothelial cell loss, vessel tortuosity, leukostasis, and capillary
blockage, dropout and hemorrhage (Tee et al., 2008).
Akimba mice
A potential transgenic mouse model of DR named ‘Akimba’ has
been developed recently by crossing Kimba mice with Akita mice
(Rakoczy et al., 2010). These mice showed key features exhibited
by the parent strains: overexpression of VEGF (as in Kimba mice)
and spontaneous type 1 diabetes (as in Akita mice). In this model,
advanced retinal lesions resembling human PDR were caused in
diabetic mice by ‘on top’ alternative approaches (e.g.
neovascularization due to transgenic expression of human
VEGF165 in photoreceptors). Interestingly, vascular changes in this
model include microaneurysms, increased prevalence of leaky
capillaries, venous beading, tortuous vessels, capillary dropout and
attenuation of vessels. Fig. 5 shows a comparison of retinal fundus,
FFA and histology of Kimba, Akita and Akimba mice.
The neovascular changes observed in the Akimba mouse are not
due to long-term hyperglycemia, as in human DR, but are due to
the presence of the human VEGF165 transgene in the
photoreceptors. Hence, this model might not be suitable for
studying the etiology of DR or the factors associated with the
development of pre-retinal neovascularization. The mechanisms
of enhanced vascular and neuronal retinal changes,
neuroprotection and the role of inflammation in Akimba mice have
not yet been studied. This newly developed model is an important
tool to improve our understanding of the complex processes
underlying the progression of DR.
Galactosemia models
Galactosemia animal models of DR are induced in rodents by
supplementing with a diet containing 30-50% galactose. Galactose-
fed rats and mice develop retinal microangiopathy that resembles
the early stages of DR (Kern and Engerman, 1995), including
pericyte loss, acellular capillaries, thickened retinal capillary BM,
IRMAs and, in dogs, also microaneurysms and intra-retinal
hemorrhages. Galactosemic mice showed increased retinal capillary
width and microaneurysms at 8 months of age. Retinal
microaneurysms, acellular capillaries, pericyte ghosts and capillary
BM thickening became increasingly prevalent in mice on the 30%
galactose diet for longer durations. The development of cataracts
has been extensively probed using galactosemic rats and mice (Kern
and Engerman, 1996a). Galactosemic rodents lack many of the
metabolic abnormalities that are characteristic of diabetes, but
develop many of the retinal complications of diabetes and thus can
be considered a valuable tool for the study of the pathogenesis of
diabetic complications.
Large animal models of DR
Diabetic dogs
Retinopathy that develops in spontaneously or experimentally
induced diabetic dogs is morphologically similar to human DR
(Kern and Mohr, 2007; Kern, 2009; Zheng and Kern, 2010). Studies
of retinopathy using dog models have used mostly type 1 diabetes
induced by alloxan, STZ, growth hormone or pancreatectomy.
Studies have also been carried out on long-term galactose-fed dogs
(Engerman and Kern, 1984). Retinal lesions reported in diabetic
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perfused) capillaries, pericyte loss, IRMAs, thicker capillary BM,
and dot and blot hemorrhages (Gardiner et al., 1994; Kern and
Engerman, 1996b). Similar to diabetic dogs, long-term galactose-
fed galactosemic dogs have retinal lesions that resemble those seen
in human DR (Takahashi et al., 1993; Kern and Engerman, 1996b;
Kobayashi et al., 1998). Galactose-fed dogs have been shown to
develop diabetes-like retinal vessel changes associated with both
the early and moderately advanced stages of retinopathy. However,
it is 3-5 years before severe retinopathy develops, accompanied by
occasional intra-retinal neovascularization, in dog models
(Engerman and Kramer, 1982; Engerman and Kern, 1984; Takahashi
et al., 1992; Wallow and Engerman, 1997). In addition, the cost,
lack of specific antibodies or molecular reagents, heightened ethical
concerns and difficulty in maintenance mean that dog models are
less useful than small animal models for the study of DR (Kobayashi
et al., 1998).
Diabetic cats
Most studies of diabetic cats involve type 1 diabetes induced by
STZ and pancreatectomy, with or without alloxan. Retinal lesions
include capillary BM thickening, increased vessel tortuosity,
capillary non-perfusion, microaneurysms, fluorescein leakage and
possibly neovascularization (Mansour et al., 1990; Hatchell et al.,
1995; Linsenmeier et al., 1998; Budzynski et al., 2005). Diabetic cats
develop only mild cataract, which allows the use of FFA and other
in vivo measurements for years after the induction of diabetes
(Salgado et al., 2000; Richter et al., 2002). Cats also exhibit retinal
hypoxia in diabetes, which might result from capillary plugging or
altered flow through microaneurysms (Linsenmeier et al., 1998).
However, the cost, lack of specific antibodies or molecular biology
reagents, and slow development of lesions has made cat models
less suitable than rodent models for studies of DR.
Diabetic pigs
The structure of the retinal vascular system in pigs is very similar
to that of humans, which makes them very useful for research on
eye diseases. Pigs developed retinal capillary BM thickening with
several ultrastructural features, such as lamellation and rarefaction
within BM, as early as 18 weeks after STZ treatment (Lee et al.,
2010). Another study of type 1 diabetic pigs reported the fairly rapid
development of features characteristic of early retinal
microvasculature changes (Hainsworth et al., 2002). Further studies
using this model might improve our understanding of DR
progression, and might provide an important platform for
investigating new treatments that prove promising in small animal
studies, before progressing to clinical trials in humans. The
disadvantages of pig models include high cost, lack of specific













Fig. 5. Comparison of retinal fundus, FFA and histology of Kimba, Akimba and Akita mice. Fundus, FFA and retinal histology of Kimba (A-C), Akimba (D-F)
and Akita (G-I) mice (courtesy of Lions Eye Institute, Perth, Australia). FFA shows the differences in retinal vasculature between Kimba (B), Akimba (E) and Akita (H)
mice. Kimba (B) and Akimba (E) mice have foci of fluorescein leakages (arrows). Akita (H) mice have sharply defined retinal vessels and retinal capillary network
with vessels radiating from the optic nerve head. Light micrographs of paraffin-embedded eyes of Kimba (C), Akimba (F) and Akita (I) mouse eyes show retinal
histology. The sections were stained with H&E. Arrows in C and F point to breaks in the RPE cells of Kimba and Akimba mouse eyes, whereas arrows in (I) point to
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the fact that the techniques for genetic characterization and
manipulation are currently less precise than in small animal
models.
Diabetic non-human primates
The structural similarity of primate eyes to human eyes makes them
potential models for research on eye diseases. The main advantage
of primate models over the other models discussed above is the
presence of the macula, an important site of damage in DR. The
most common primate models used for studies of DR include
rhesus monkeys with diabetes induced by alloxan, STZ or total
pancreatectomy. Cynomolgus monkeys (Macaca fascicularis) and
obese rhesus monkeys (Macaca mulatta) that develop diabetes
spontaneously have also been used. Evidence shows that
retinopathy develops very slowly in diabetic non-human primates
(as in humans). STZ- or pancreatectomy-induced diabetic monkeys
studied for up to 15 years showed retinal ischemia and defects in
the BRB and macula. However, these models lack vascular lesions
observed in human DR (Tso et al., 1988). Studies of aged monkeys
with spontaneous diabetes revealed IRMAs and macular edema.
Microaneurysms were also associated with the areas of non-
perfusion (Johnson et al., 2005). Investigations on type 2 diabetic
primate models revealed hemorrhages, large areas of retinal
capillary non-perfusion, microaneurysms, cotton wool spots, intra-
retinal hemorrhages and hard exudates in the macula (Kim et al.,
2004). To date, retinal neovascularization or neuronal degeneration
has not been reported in diabetic non-human primates.
Despite the structural similarity of the eye in humans and non-
human primates, these models are not always preferred over other
animal models owing to several limitations. Non-human primates
are difficult to manipulate genetically, and molecular reagents for
experimental studies are lacking. They also have a longer gestational
period and lower birth rates. Other disadvantages include slow
progression of DR, increased maintenance costs and the ethical
issues of using non-human primates as animal models.
Future directions
As outlined in this Perspective, animal models of DR are important
tools that will continue to enhance our understanding of the
pathogenesis of DR, as well as the development of novel therapeutic
approaches. However, it is clear that there is still no perfect animal
model that recapitulates all aspects of human DR. Although most
of the models discussed have demonstrated the basic features of
NPDR, the key feature of human PDR – pre-retinal
neovascularization secondary to diabetes per se – is not
recapitulated in diabetic animal models. Nevertheless, current
clinical tools to treat existing PDR are relatively successful, and thus
the focus of future research should be to inhibit development of
the early stages of the retinopathy, thereby preventing the
subsequent progression to advanced retinopathy. Notably, retinal
thickening (consistent with DME) has been detected in a small
number of available models such as monkeys. Vision loss or
impairment is also now being studied in mice and rats using the
optokinetic response (Thomas et al., 2010); investigating the cause
of a diabetes-induced reduction in visual function might provide
new insight into the causes of vision loss in diabetic humans.
Some investigators feel that a remaining challenge is to develop
animal models that mimic the progression of DR from the non-
proliferative to proliferative stage, as in human DR (Rakoczy et al.,
2010; Li et al., 2010). This might be accomplished by accelerating
the retinopathy in models through superimposing a particular
genetic or metabolic abnormality on top of diabetes (e.g. as in
eNOS–/– or Akimba mice). Nevertheless, the extent to which the
underlying pathogenesis of retinopathy in such models mimics that
of human DR will be an important issue to address.
The application of appropriate techniques for the
characterization of DR is an equally important challenge for the
future. The current methods for in vivo characterization of DR,
including ERG, FP, FFA and OCT, can monitor progressive
pathological changes (vascular and non-vascular) in the same
animal over time, but new methods that provide additional
information (e.g. retinal vascular caliber measurements) are needed.
In terms of clinical issues, many areas of uncertainty remain. It
is well known that, despite controlling systemic risk factors of
hyperglycemia and hypertension, many patients still progress to
develop the vision-threatening stages of DR (either PDR or DME).
The current standard of care is laser therapy, which is inherently
destructive, associated with side effects and is ineffective in
reversing visual loss. New approaches, including intraocular
administration of anti-VEGF agents, are promising but have
potential risks (Cheung et al., 2010). Thus, preventing DR and
targeting early stages of DR is desirable. For example, the ability to
provide effective topical therapies that target multiple pathways
underlying retinal neovascularization and edema could further
improve the current management strategies for DR. Development
of such therapies requires substantial basic and experimental
studies, for which appropriate animal models of DR are essential.
Conclusions
New and cost-effective therapies for treating DR, particularly the
early stages of DR, are urgently needed. Animal models that
develop lesions that are characteristic of human DR will continue
to play a crucial role in understanding pathogenesis and for testing
new therapies before clinical trials. The success of each study
depends largely on the choice of the appropriate animal model,
which, in turn, is driven by experimental design and focus. Key
features to consider when choosing an animal model of DR include:
the structural and biochemical features of the visual system
compared with humans; the ability to perform genetic
manipulations; the availability and cost of the model; methods
available for disease characterization and validation; the time
course of pathological changes; and ethical, moral and legal issues.
Overcoming current challenges in DR research requires more
extensive experiments with the most promising models,
incorporating advanced techniques for more accurate phenotyping.
This approach will ultimately help to identify the best systems to
better understand, prevent and treat the human disease.
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